Oncological Outcomes after Liver Venous Deprivation for Colorectal Liver Metastases: A Single Center Experience.

colorectal liver metastasis future liver remnant liver venous deprivation (LVD) oncological outcomes

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
08 Jan 2021
Historique:
received: 06 12 2020
revised: 06 01 2021
accepted: 07 01 2021
entrez: 12 1 2021
pubmed: 13 1 2021
medline: 13 1 2021
Statut: epublish

Résumé

Colorectal liver metastases (CRLM) are the major cause of death in patients with colorectal cancer (CRC). The cornerstone treatment of CRLM is surgical resection. Post-operative morbidity and mortality are mainly linked to an inadequate future liver remnant (FLR). Nowadays preoperative portal vein embolization (PVE) is the most widely performed technique to increase the size of the future liver remnant (FLR) before major hepatectomies. One method recently proposed to increase the FLR is liver venous deprivation (LVD), but its oncological impact is still unknown. The aim of this study is to report first short- and long-term oncological outcomes after LVD in patients undergoing right (or extended right) hepatectomy for CRLM. Seventeen consecutive patients undergoing LVD between July 2015 and May 2020 before an (extended) right hepatectomy were retrospectively analyzed from an institutional database. Post-operative and follow-up data were analyzed and reported. Primary outcomes were 1-year and 3-year overall survival (OS) and hepatic recurrence (HR). Postoperative complications occurred in 8 patients (47%). No deaths occurred after surgery. HR occurred in 9 patients (52.9%). 1-year and 3-year OS were 87% (95% confidence interval [CI]: ±16%) and 60.3%, respectively (95% CI: ±23%). Median Disease-Free Survival (DFS) was 6 months (CI 95%: 4.7-7.2). With all the limitations of a retrospective study with a small sample size, LVD showed similar oncological outcomes compared to literature reports for Portal Vein Embolization (PVE).

Identifiants

pubmed: 33429913
pii: cancers13020200
doi: 10.3390/cancers13020200
pmc: PMC7826613
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Cardiovasc Intervent Radiol. 2013 Feb;36(1):25-34
pubmed: 22806245
Surgery. 2011 May;149(5):680-8
pubmed: 21316725
Hepatology. 2001 Aug;34(2):267-72
pubmed: 11481611
Surgery. 1990 May;107(5):521-7
pubmed: 2333592
Ann Surg. 2002 Jun;235(6):759-66
pubmed: 12035031
Hepatology. 2003 Jul;38(1):258-66
pubmed: 12830009
HPB (Oxford). 2012 Jul;14(7):461-8
pubmed: 22672548
Ann Surg. 2008 Jan;247(1):125-35
pubmed: 18156932
Gut. 2005 Feb;54(2):289-96
pubmed: 15647196
Ann Surg. 2013 Mar;257(3):377-82
pubmed: 22895397
Eur J Surg Oncol. 2017 Jan;43(1):32-41
pubmed: 27283892
Ann Surg. 2015 Feb;261(2):e45-6
pubmed: 24670841
Hepatobiliary Surg Nutr. 2020 Oct;9(5):564-576
pubmed: 33163507
HPB (Oxford). 2011 Aug;13(8):528-35
pubmed: 21762295
Liver Cancer. 2016 Nov;6(1):80-89
pubmed: 27995092
Hepatology. 1997 Nov;26(5):1176-81
pubmed: 9362359
Br J Surg. 1989 Jun;76(6):545-8
pubmed: 2474356
J Clin Oncol. 2005 Nov 20;23(33):8490-9
pubmed: 16230676
HPB (Oxford). 2017 Sep;19(9):775-784
pubmed: 28625391
Surgery. 2018 Jun;163(6):1257-1263
pubmed: 29502872
Front Oncol. 2020 Aug 21;10:1391
pubmed: 32974141
World J Surg Oncol. 2020 Jun 24;18(1):140
pubmed: 32580729
Br J Radiol. 2006 Jun;79(942):473-8
pubmed: 16714748
Ann Surg Oncol. 2016 Oct;23(11):3709-3717
pubmed: 27272106
Ann Surg. 2008 Jan;247(1):49-57
pubmed: 18156923
World J Clin Cases. 2018 Nov 26;6(14):716-734
pubmed: 30510936
AJR Am J Roentgenol. 1998 Oct;171(4):1037-9
pubmed: 9762992
World J Surg. 2015 Dec;39(12):2990-8
pubmed: 26304608
Ann Surg. 2015 Apr;261(4):723-32
pubmed: 25493362
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Saudi J Anaesth. 2019 Apr;13(Suppl 1):S31-S34
pubmed: 30930717
Eur Radiol. 2017 Aug;27(8):3343-3352
pubmed: 28101681
Eur Radiol. 2016 Dec;26(12):4259-4267
pubmed: 27090112
Br J Cancer. 2009 Feb 24;100(4):617-22
pubmed: 19209170
Hepatobiliary Surg Nutr. 2019 Aug;8(4):329-337
pubmed: 31489302
Br J Surg. 2014 Aug;101(9):1129-34; discussion 1134
pubmed: 24947768
Curr Oncol Rep. 2020 May 16;22(6):59
pubmed: 32415401
Surgery. 2020 Nov;168(5):976-977
pubmed: 32307096
Ann Surg. 2012 Nov;256(5):812-7; discussion 817-8
pubmed: 23095626
Visc Med. 2017 Dec;33(6):426-433
pubmed: 29344516
Surgery. 2020 Jun;167(6):917-923
pubmed: 32014304
Surgery. 2011 May;149(5):713-24
pubmed: 21236455

Auteurs

Salah Khayat (S)

Division of HBP Surgery and Transplantation, Department of Surgery, St. Eloi Hospital, Montpellier University Hospital-School of Medicine, 34090 Montpellier, France.

Gianluca Cassese (G)

Division of HBP Surgery and Transplantation, Department of Surgery, St. Eloi Hospital, Montpellier University Hospital-School of Medicine, 34090 Montpellier, France.
Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Napoli, Italy.

François Quenet (F)

Department of Surgical Oncology, Cancer Institute of Montpellier (ICM) 208, 34298 Montpellier, France.

Christophe Cassinotto (C)

Division of Interventional Radiology, Department of Radiology, St. Eloi Hospital, Montpellier University Hospital-School of Medicine, 34090 Montpellier, France.

Eric Assenat (E)

Service d'Oncologie Médicale, CHU Saint Eloi, 34090 Montpellier, France.

Francis Navarro (F)

Division of HBP Surgery and Transplantation, Department of Surgery, St. Eloi Hospital, Montpellier University Hospital-School of Medicine, 34090 Montpellier, France.

Boris Guiu (B)

Division of Interventional Radiology, Department of Radiology, St. Eloi Hospital, Montpellier University Hospital-School of Medicine, 34090 Montpellier, France.

Fabrizio Panaro (F)

Division of HBP Surgery and Transplantation, Department of Surgery, St. Eloi Hospital, Montpellier University Hospital-School of Medicine, 34090 Montpellier, France.

Classifications MeSH